FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
China86 participantsStarted 2026-02-01
Plain-language summary
This study is a prospective, multicenter Phase II trial evaluating a personalized treatment strategy for patients with unresectable hepatocellular carcinoma (HCC). The study uses a metabolic classification system called the fatty acid degradation (FAD) subtype to guide therapy selection. Patients will be assigned to different treatment groups based on their tumor's FAD subtype, determined through RNA-seq analysis of the tumor tissue obtained from liver biopsy.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adults ≥18 years of age who voluntarily agree to participate and sign informed consent.
✓. Histologically or cytologically confirmed hepatocellular carcinoma (HCC).
✓. Unresectable or not suitable for curative local therapy, or progression after prior surgery or local therapy.
✓. BCLC stage B or C.
✓. No prior systemic therapy for HCC.
✓. At least one measurable lesion according to RECIST v1.1.
✓. Availability of fresh or archival tumor tissue for FAD subtype testing; if not available at screening, MRI fat fraction may be used temporarily.